OpenClinica Launches Program Designed to Match OpenClinica’s Enterprise Technology with CRO Services
OpenClinica
is launching a program designed to match OpenClinica’s Enterprise technology with Contract Research Organization (CRO) services to deliver enhanced customer offerings.
Ben Baumann, OpenClinica’s director of business development, says this program will be appropriate for both domestic and international organizations.
“As the leader in using open source technology to improve clinical research, OpenClinica, is expanding its capabilities and reach by partnering with other forward thinking organizations who understand the substantial value that a professionally implemented and well developed open source solution can bring to clinical trial operations,” Baumann said.
OpenClinica is expanding the OpenClinica Partner Program to:
- Provide a framework for organizations offering value-added services around OpenClinica.
- Leverage the strengths of each party and bring these strengths to bear in customer solutions that are higher quality than they would be otherwise.
- Drive the success of our partners and increase the value received from selecting OpenClinica as their electronic data capture (EDC) and clinical data management platform (CDM).
OpenClinica is presently fielding inquiries from companies interested in learning more about the Partner Program. For more information go to:
https://www.openclinica.com/partner-inquiry
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
